PTK7 overexpression has been reported in multiple cancers40–45, and previous reports have shown that an antibody-drug conjugate (ADC) targeting PTK7 was effective in treatment of triple-negative breast cancer, ovarian cancer, and non-small cell lung cancer46,47. Here, PTK7 is linked to ovarian carcinoma.